HC Wainwright set a $5.00 target price on Protalix BioTherapeutics (NYSEAMERICAN:PLX) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the stock.
Separately, Zacks Investment Research lowered shares of Protalix BioTherapeutics from a hold rating to a sell rating in a research report on Saturday, March 10th.
Protalix BioTherapeutics traded up $0.04, reaching $0.45, during mid-day trading on Friday, MarketBeat Ratings reports. The company had a trading volume of 925,828 shares, compared to its average volume of 784,105. Protalix BioTherapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $0.48.
Protalix BioTherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Wednesday, May 9th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. The company had revenue of $4.55 million during the quarter, compared to analyst estimates of $4.40 million. During the same quarter in the prior year, the business earned ($0.48) EPS.
A hedge fund recently bought a new stake in Protalix BioTherapeutics stock. Opaleye Management Inc. purchased a new stake in shares of Protalix BioTherapeutics (NYSEAMERICAN:PLX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned about 1.27% of Protalix BioTherapeutics as of its most recent filing with the Securities & Exchange Commission.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.